Dr. Mallikarjun Sundaram is the President & CEO of Mitra Biotech Private Limited since its inception in 2009. Prior to founding Mitra, he was the scientific co-founder and head of drug discovery at Momenta Pharmaceuticals, a publicly traded biotechnology company in Cambridge, MA, USA. He obtained his B.Pharm from the Indian Institute of Technology, Banaras Hindu University in 1994. He completed his PhD in Biochemistry from the University of Utah, Salt Lake City, USA in 1999. He pursued his post-doctoral research at Massachusetts Institute of Technology, Cambridge MA from January 2000 till September 2001.
He received his MBA from the Wharton Business School at the University of Pennsylvania in 2006. Work carried out during his post-doctoral research lead to the foundation of Momenta Pharmaceuticals in October 2001. He was a scientific co-founder of the company and was one of the four first employees to join the company in 2001. The first product developed by Momenta, M-Enoxaparin, was approved in June 2010 and brings in revenue of US$ 1.8 Billion per year in U.S. alone. Besides M Enoxaparin ™, Momenta has developed other drugs such as M-Copaxone™, a drug in the Oncology space and another drug in the cardiovascular space- all in various stages of clinical trials. In addition to his responsibility at Momenta, He is also an adjunct faculty in the department of Bioengineering at the Massachusetts.
Dr. Mallik has co-authored over 25 peer reviewed publications, and holds 15 global patents. He is an active member influencing and participating in events related to social causes. He, along with many other members at Mitra is a key patron of One Billion Literates, an NGO that promotes child education and helps set up schools for underprivileged children. He is a regular at charity related marathons like TCS 10K, Mumbai Marathon etc.